Schedule

This session will showcase the latest advances in experimental platforms that reduce reliance on animal testing while improving human relevance. Speakers will highlight innovative organoid models, microphysiological systems (MPS), and in chemico approaches that offer mechanistic insight and translational value in human disease research. Dr. Ellen Shrock, University of Washington Antibody Immunodominance is Germline-Encoded and Shapes Viral Evolution Dr. Weida Tong, NCTR/FDA From Animal to Algorithm: Assessing Drug-Induced Liver Injury with AI Dr. Shehzad Z. Sheikh, University of North Carolina at Chapel Hill Metabolic Rewiring of Fibroblasts Fuels Fibrostenotic Crohn's Disease

• Speaker: Dr. Ellen Shrock
• Speaker: Dr. Weida Tong
• Speaker: Dr. Shehzad Z. Sheikh

The Complement Animal Research In Experimentation (Complement-ARIE) Program

• Speaker: Dr. Thaddeus (Thad) Schug

This session explores how artificial intelligence, machine learning, and in silico modeling are transforming health prediction and chemical risk assessment. Talks will focus on leveraging AI for drug repurposing, simulating complex biological systems, and integrating large datasets to refine predictive frameworks like Adverse Outcome Pathways. Dr. James Glazier, Indiana University Bloomington Virtual Tissues as IVIVE Engines: Turning NAM Evidence into Predictive Toxicology and Drug Response Dr. Carolina González, Scripps Research Institute Advancing Drug Repositioning with Explainable Graph Neural Networks

• Speaker: Dr. James Glazier
• Speaker: Dr. Carolina González